Biohit Concludes Statutory Co-operation NegotiationsMain Market, 2012-10-01 11:00 CEST --
Biohit Oyj stock exchange release, 1 October 2012 at EET 12:00 am
The statutory co-operation negotiations concerning Biohit employees in Finland that started in September 2012 have been concluded today. As a result of co-operation negotiations, the company has decided to execute operative savings, modify job descriptions and to reduce two people to achieve cost savings. The decisions made in and during the statutory co-operation negotiations will generate EUR 310.000 savings on an annual level. “I thank the staff representatives for their constructive contribution in these statutory co-operation negotiations”, says Semi Korpela, CEO, Biohit Oyj.
Biohit offers an outplacement program for people impacted by the co-operation negotiations.
Contact details:
Semi Korpela, M. Sc. Econ., President & CEO
Biohit Oyj, tel.: +358 9 773 861, semi.korpela@biohit.fi
Biohit Oyj is a globally operating Finnish biotechnology company that was established in 1988. Biohit’s mission is “Innovating for Health” and “Cancer Prevention”. The purpose of the company is to produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. Our duty is also to innovate and develop the marketing and availability of our products and services. www.biohithealthcare.com
|